Related Experiment Video
Updated: Aug 14, 2026

A Facile Protocol to Generate Site-Specifically Acetylated Proteins in Escherichia Coli
Published on: December 9, 2017
Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262
K M Bohren1, J L Page, R Shankar
1Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030.
Abstract:
Human aldose reductase (EC 1.1.1.21) and aldehyde reductase (EC 1.1.1.2) are implicated in the development of diabetic complications by a variety of mechanisms, and a number of drugs to inhibit these enzymes have been proposed for the therapy and prevention of these complications. To probe the structure and function of these two enzymes, we used site-directed mutagenesis in the cDNAs of both enzymes to replace lysine 262 with methionine. Wild-type and mutant enzymes were overexpressed in Escherichia coli and purified by anion exchange and affinity chromatography. N-terminal sequence analysis, Western blots, and kinetic studies confirmed the identity of the recombinant wild-type enzymes with the native human placental and liver enzymes. Recombinant aldose reductase (hAR) and aldehyde reductase (hGR) have apparent kinetic constants virtually identical to their respective native enzymes. The mutant aldose reductase (hARK262 greater than M) shows a 66-fold increase in Km for NADPH with respect to the wild type (1.9 +/- 0.4 microM versus 125 +/- 14 microM), whereas the Km for DL-glyceraldehyde increased 35-fold (20 +/- 2 versus 693 +/- 41 microM). The same constants for the mutant aldehyde reductase (hGRK262 greater than M) increased 97- and 86-fold, respectively (from 2.0 +/- 0.4 to 194 +/- 16 microM and from 1.6 +/- 0.4 to 137 +/- 3 mM). These results indicate that lysine 262 in aldose reductase and aldehyde reductase is crucial to their catalytic activity by affecting co-factor binding.
Insights
Lysine 262 is essential for human aldose reductase and aldehyde reductase activity, impacting cofactor binding. Mutating this residue significantly reduces enzyme function, offering insights into diabetic complication therapies.
Area of Science:
- Biochemistry
- Enzymology
- Molecular Biology
Background:
- Human aldose reductase (hAR) and aldehyde reductase (hGR) are implicated in diabetic complications.
- Inhibiting these enzymes is a therapeutic strategy for diabetic complications.
Purpose of the Study:
- To investigate the role of lysine 262 in hAR and hGR structure and function.
- To understand the impact of lysine 262 mutations on enzyme kinetics and cofactor binding.
Main Methods:
- Site-directed mutagenesis was used to replace lysine 262 with methionine in hAR and hGR cDNAs.
- Wild-type and mutant enzymes were overexpressed in E. coli and purified.
- Kinetic studies (Km values) were performed to assess enzyme activity and cofactor binding.
Main Results:
- Mutant hAR (K262M) showed a 66-fold increase in Km for NADPH and a 35-fold increase for DL-glyceraldehyde.
- Mutant hGR (K262M) exhibited a 97-fold increase in Km for NADPH and an 86-fold increase for DL-glyceraldehyde.
- These changes indicate lysine 262 is critical for cofactor binding and catalytic activity.
Conclusions:
- Lysine 262 is crucial for the catalytic activity of both human aldose reductase and aldehyde reductase.
- The mutation at lysine 262 significantly impairs cofactor binding, affecting enzyme function.
- Understanding this residue's role can inform the development of targeted inhibitors for diabetic complications.
Related Concept Videos
Ligand Binding and Linkage
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...

